How TMEM106B, GRN and TDP-43 interact in frontotemporal dementia

The TMEM106B-GRN-TDP43 triad: leveraging human samples and humanized models to unravel FTLD-TDP disease mechanisms

NIH-funded research Flanders Interuniv Inst Biotechnology · NIH-11189602

Looking at how three proteins—TMEM106B, progranulin (GRN), and TDP-43—work together to better understand frontotemporal dementia in people who develop early-onset dementia.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionFlanders Interuniv Inst Biotechnology NIH-funded
Lab location1 site (Gent, Belgium)
Project IDNIH-11189602 on NIH RePORTER

What this research studies

This project uses human brain tissue samples and humanized lab models to uncover why TDP-43 protein clumps form in frontotemporal lobar degeneration (FTLD-TDP). Researchers will compare samples from people with GRN mutations and different TMEM106B genetic variants and will build humanized cell and animal models that better reflect human microglia and neurons. Because standard mouse models do not reproduce the TDP-43 pathology seen in patients, the team will introduce human genetic elements and patient-derived materials to recreate disease features. The goal is to reveal how these genetic factors interact to cause neurodegeneration and to create better models for testing future therapies.

Who could benefit from this research

Good fit: People diagnosed with frontotemporal dementia, carriers of GRN mutations, or family members at risk for FTLD-TDP would be the best candidates to provide samples or take part.

Not a fit: People whose dementia is clearly due to Alzheimer's disease or other non-TDP-43 causes may not directly benefit from this research.

Why it matters

Potential benefit: If successful, this work could produce more accurate human-based models and point to new targets for diagnostics or treatments for frontotemporal dementia.

How similar studies have performed: Previous GRN-deficient mouse studies caused neuroinflammation but did not produce the TDP-43 brain clumps seen in patients, so using human samples and humanized models is a newer approach to address that shortcoming.

Where this research is happening

Gent, Belgium

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.